Literature DB >> 6311492

Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.

P C Appelbaum, J Tamim, G A Pankuch, R C Aber.   

Abstract

Susceptibility of 324 isolates of nonfermentative gram-negative bacteria to cephalothin, cefamandole, cefoxitin, ceftazidime, cefsulodin, and azthreonam was determined by agar dilution and disc diffusion techniques. With the exception of Moraxella species, first- and second-generation cephalosporins were minimally active against nonfermenters tested. Cefsulodin and azthreonam were mainly active against Pseudomonas aeruginosa. In contrast, ceftazidime and ceftriaxone exhibited wider activity spectra. Cefsulodin and ceftazidime were the most active against P. aeruginosa, followed by azthreonam and ceftriaxone. Ceftazidime was the only drug with significant activity against Pseudomonas maltophilia and Pseudomonas fluorescens/Pseudomonas putida, and was also the most active against Pseudomonas cepacia. Acinetobacter calcoaceticus and Alcaligenes strains were most sensitive to ceftazidime, followed by ceftriaxone and azthreonam. Ceftriaxone was the most active against moraxellas, followed by cefamandole/cefoxitin, ceftazidime, cephalothin, cefsulodin, and azthreonam. Ceftazidime was the most active against uncommonly isolated nonfermenters. Results observed in this study reflect a potential use for ceftazidime in therapy of infections caused by most gram-negative nonfermenters; therapy with cefsulodin and azthreonam in nonfermenter infections should be restricted to those caused by P. aeruginosa, and that with ceftriaxone reserved for non-P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311492     DOI: 10.1159/000238217

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

1.  Rapid differentiation of fermentative from nonfermentative gram-negative bacilli in positive blood cultures by an impedance method.

Authors:  T C Chang; A H Huang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

2.  Antimicrobial susceptibility of Bordetella avium and Bordetella bronchiseptica isolates.

Authors:  J E Mortensen; A Brumbach; T R Shryock
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

3.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Another look at trimethoprim-sulfamethoxazole: its role in parenteral therapy.

Authors:  F R Sattler; J S Remington
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

Review 5.  The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

Authors:  O C Tablan; W J Martone; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

Review 6.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

7.  Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.

Authors:  M A Visalli; M R Jacobs; T D Moore; F A Renzi; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 9.  Human infections associated with Bordetella bronchiseptica.

Authors:  B F Woolfrey; J A Moody
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

Review 10.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.